Ascendis Pharma A (ASND) Share-based Compensation (2014 - 2026)

Ascendis Pharma A has reported Share-based Compensation for 13 years, with the latest figure at $35.5 million in Q1 2026.

• Quarterly Share-based Compensation rose 32.19% year-over-year to $35.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $140.2 million (up 25.78% YoY) and the FY2025 annual result came in at $135.2 million, up 32.49% from the prior year.
• Share-based Compensation advanced to $35.5 million in Q1 2026 per ASND's latest filing, from $34.9 million in the prior quarter.
• Over five years, Share-based Compensation peaked at $35.8 million in Q3 2025 and troughed at $13.6 million in Q3 2022.
• A 5-year average of $24.2 million and a median of $22.4 million in 2022 frame the typical range for Share-based Compensation.
• The sharpest annual moves came in 2023 and 2024: Share-based Compensation slumped 34.44% in 2023, then soared 63.7% in 2024.
• Over 5 years, Share-based Compensation stood at $14.2 million in 2022, then rose by 20.93% to $17.1 million in 2023, then jumped by 63.7% to $28.0 million in 2024, then grew by 24.44% to $34.9 million in 2025, then advanced by 1.92% to $35.5 million in 2026.
• According to Business Quant data, Share-based Compensation over the past three periods registered $35.5 million, $34.9 million, and $35.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.